Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

Montgomery, William; Treuer, Tamás; Karagianis, Jamie; Ascher-Svanum, Haya; Harrison, Gavan

doi:10.2147/ppa.s27344

Cited by 26 publications

(24 citation statements)

References 69 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a review on relevant studies did not find a substantial difference, if any at all. Further rigorous studies are needed to fully address this issue [82,83].…”

Section: Weight Gain Due To Olanzapine (Oral and Depot Formulation)mentioning

confidence: 99%

Weight gain and antipsychotics: a drug safety review

Musil

Obermeier²,

Russ

et al. 2014

Expert Opinion on Drug Safety

155

111

View full text Add to dashboard Cite

Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews ranking clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone, quetiapine, risperidone and sertindole in the middle, and aripiprazole, lurasidone and ziprasidone with the lowest risk. Number needed to harm varied considerably in our meta-analysis. Younger patients and patients with a lower baseline body mass index are most vulnerable. The greatest amount of weight gain occurs within the first weeks of treatment. AIWG occurs in all diagnostic groups and is also common in treatment with first-generation antipsychotics; therefore, awareness of this adverse event is essential for anyone prescribing antipsychotics.

show abstract

“…However, a review on relevant studies did not find a substantial difference, if any at all. Further rigorous studies are needed to fully address this issue [82,83].…”

Section: Weight Gain Due To Olanzapine (Oral and Depot Formulation)mentioning

confidence: 99%

Weight gain and antipsychotics: a drug safety review

Musil

Obermeier²,

Russ

et al. 2014

Expert Opinion on Drug Safety

155

111

View full text Add to dashboard Cite

show abstract

“…Patient preference and reduction in nursing burden are the other advantages with oral disintegrating tablets of olanzapine. 5 Limitations for use of olanzapine include risk of the adverse events like weight gain, dyslipidemia and diabetes. Olanzapine oral disintegrating tablets have an advantage over standard tablet in this regard.…”

Section: Olanzapine Mouth Dissolving Tabletsmentioning

confidence: 99%

Advantages of modified drug delivery system in psychiatry

Patil¹

2013

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Non-compliance is a common problem in chronic diseases including psychiatric disorders. Various attempts have been made for improving adherence in psychiatry; one of them being simplifying dosage regimen by designing modified dosage formulation. For example, depot formulation, oral disintegrating tablets or extended release formulations are some of the strategies for improving compliance in psychiatry patients. Modified dosage formulations also have some other advantages too. For example, oral disintegrating tablet of olanzapine cause lesser weight gain compared to standard olanzapine tablet while Zolpidem extended release tablet provides better sleep maintenance in middle of night. This article reviews some of the modified dosage formulations in psychiatric diseases with their advantages. [Int J Basic Clin Pharmacol 2013; 2(4.000): 368-370

show abstract

“…Patients may spit out liquid medication because of its taste or find injectable dosage form unacceptable or contraindicated. Other problems associated with the administration of drug to psychotic patients may include situations in which patient is agitated or shows difficulty in swallowing 18 . Carbamazepine is an antiepileptic drug used in the treatment of psychomotor seizures and trigeminal neuralgia.…”

Section: Introductionmentioning

confidence: 99%

An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine

Mishra

Rohera

2016

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

The objective of the present study was to design and develop a formulation for orally disintegrating tablets (ODTs) of carbamazepine using quality by design principles. The target product profile (TPP) and quality target product profile (QTPP) of ODTs were identified. Risk assessment was carried out by leveraging prior knowledge and experience to define the criticality of factors based on their impact by Ishikawa fishbone diagram and preliminary hazard analysis tool. Box-Behnken response surface methodology was used to study the effect of critical factors on various attributes of ODTs. The independent factors selected were compression pressure (X), concentration of sublimating agent (volatile material) (X), disintegrant concentration (X) and the responses were tablet crushing strength, tablet porosity, disintegration time, water absorption time, tablet friability and drug dissolution. ANOVA and lack of fit test illustrated that selected independent variables had significant effect on the response variables, and excellent correlation was observed between actual and predicted values. Optimization by desirability function indicated that compression pressure, X (1534 lbs), ammonium bicarbonate concentration, X (7.68%) and Kollidon CL-SF concentration, X (6%) were optimum to prepare ODT formulation of carbamazepine of desired attributes complying with QTPP. Thus, in the present study, a high level of assurance was established for ODT product quality and performance.

show abstract

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

Cited by 26 publications

References 69 publications

Weight gain and antipsychotics: a drug safety review

Weight gain and antipsychotics: a drug safety review

Advantages of modified drug delivery system in psychiatry

An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine

Contact Info

Product

Resources

About